Patrick J. Loll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Patrick J. Loll has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Grace Brannigan
Rutgers, The State University of New Jersey
1 shared publication Jin Xi
The ‖Graduate Program in Biochemistry, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102
1 shared publicationKimberly C. Grasty
The ‖Graduate Program in Biochemistry, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102
1 shared publicationL. Sangeetha Vedula
Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
1 shared publicationMatthew J. Rossi
The ‖Graduate Program in Biochemistry, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102
1 shared publicationMichael A. Hall
The ‖Graduate Program in Biochemistry, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102
1 shared publication
Latest Publications
- Open Access
- 1 September 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (36) , 24176-24184
A Unitary Anesthetic Binding Site at High Resolution
- 1 September 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (36) , 24176-24184
Open AccessA Unitary Anesthetic Binding Site at High Resolution
- 17 July 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 65 (8) , 832-838
Structure of ristocetin A in complex with a bacterial cell-wall mimetic
Antimicrobial drug resistance is a serious public health problem and the development of new antibiotics has become an important priority. Ristocetin A is a class III glycopeptide antibiotic that is used in the diagnosis of von Willebrand disease and which has served as a lead compound for the development of new antimicrobial therapeutics. The 1.0 A resolution crystal structure of the complex between ristocetin A and a bacterial cell-wall peptide has been determined. As is observed for most other glycopeptide antibiotics, it is shown that ristocetin A forms a back-to-back dimer containing concave binding pockets that recognize the cell-wall peptide. A comparison of the structure of ristocetin A with those of class I glycopeptide antibiotics such as vancomycin and balhimycin identifies differences in the details of dimerization and ligand binding. The structure of the ligand-binding site reveals a likely explanation for ristocetin A's unique anticooperativity between dimerization and ligand binding.
- 17 July 2009
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 65 (8) , 832-838
Structure of ristocetin A in complex with a bacterial cell-wall mimetic
Antimicrobial drug resistance is a serious public health problem and the development of new antibiotics has become an important priority. Ristocetin A is a class III glycopeptide antibiotic that is used in the diagnosis of von Willebrand disease and which has served as a lead compound for the development of new antimicrobial therapeutics. The 1.0 A resolution crystal structure of the complex between ristocetin A and a bacterial cell-wall peptide has been determined. As is observed for most other glycopeptide antibiotics, it is shown that ristocetin A forms a back-to-back dimer containing concave binding pockets that recognize the cell-wall peptide. A comparison of the structure of ristocetin A with those of class I glycopeptide antibiotics such as vancomycin and balhimycin identifies differences in the details of dimerization and ligand binding. The structure of the ligand-binding site reveals a likely explanation for ristocetin A's unique anticooperativity between dimerization and ligand binding.